ENANTA PHARMACEUTICALS INC (ENTA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$12.58

From 52W high−27.60%

Volume428232.00

Market cap$355.33M

P/E (TTM)—

P/S (TTM)5.4x

Div yield—

Key dataSep 18, 2026

Open

$12.58

From 52W high

−27.60%

Volume

428232.00

Market cap

$355.33M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.8x

P/E (TTM)

—

RSI (14)

39.2

MomentumView details →

1D Return

−2.56%

YTD Return

−21.91%

SummaryUpdated Jun 1, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a biotechnology company founded in 1995 and headquartered in Watertown, Massachusetts. The company specializes in discovering and developing small molecule drugs for treating viral infections and liver diseases. Enanta went public in March 2013 and has established itself as a focused developer of antiviral therapeutics, with a particular emphasis on respiratory viruses and hepatitis treatments. The company operates primarily as a research and development organization, with revenue generated through royalty agreements from previously developed drugs and ongoing clinical development programs.

Ask drillr about ENANTA PHARMACEUTICALS INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.8x

EV/Sales

3.4x

P/S (TTM)

5.4x

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

98.15%

Net Margin

−96.89%

EBITDA Margin

−71.24%

ROE (TTM)

−62.56%

ROA (TTM)

−21.30%

Asset Turnover

0.21x

GrowthView details →

Revenue YoY

+0.70%

EPS YoY

+44.34%

FCF YoY

+15.22%

Revenue CAGR 3Y

−8.82%

EPS CAGR 3Y

+29.93%

EBITDA YoY

+43.59%

MomentumView details →

1D Return

−2.56%

YTD Return

−21.91%

1Y Return

+61.19%

RSI (14)

39.2

vs 50D SMA

−7.23%

vs 200D SMA

−9.40%

Capital & dividendView details →

Debt/Equity

0.55x

Current Ratio

3.76x

Quick Ratio

3.76x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.67

EPS Surprise

−31.50%

Beats (12Q)

7/12

Next Q EPS Est

−$0.77

Avg Surprise (4Q)

−5.89%

Rev Surprise

−14.34%

Financials snapshotView financials →

Revenue (TTM)

65.26M

Net Income (TTM)

−63.23M

Op. CF (TTM)

−35.32M

Next earningsNov 16, 2026 →

Latest newsMore news →

Enanta Pharmaceuticals reported a Q3 2026 loss of $0.67 per share, missing the Zacks Consensus Estimate of a loss of $0.37, and compared to a loss of $0.85 per share a year ago.41d ago

Similar companies

X4 Pharmaceuticals, Inc.XFOR Agenus Inc.AGEN Shanghai Bio-heart Biological Technology Co., Ltd.02185.HK Sirnaomics Ltd.02257.HK Ocugen, Inc.OCGN Alpha Tau Medical Ltd.DRTSW Find similar companies →

Latest newsMore news →

Entain launched a consultation to cut around 400 customer care jobs, about a fifth of its 2,000-strong global customer care workforce across 11 countries including the UK, citing increased UK gambling taxes.4d ago Enanta Pharmaceuticals reported a Q3 2026 loss of $0.67 per share, missing the Zacks Consensus Estimate of a loss of $0.37, and compared to a loss of $0.85 per share a year ago.41d ago